Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Published: April 16, 2026 by: CNBC
Sentiment: Positive
Investors are starting to focus on what will replace compounded GLP-1 driven growth for telehealth companies like Hims & Hers Health. Peptides are gaining attention as a potential new growth vector, despite clinical evidence for efficacy being limited.
Read More
Hims & Hers shares jump as FDA begins review of restricted peptide compounds
Published: April 16, 2026 by: Proactive Investors
Sentiment: Positive
Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration (FDA) moved to begin a formal review process that could eventually reshape the regulatory status of several wellness peptides used in compounding pharmacies. The FDA announced it will hold meetings on July 23 and 24 with its Pharmacy Compounding Advisory Committee to discuss whether multiple peptide-related bulk drug substances should be considered for possible inclusion on the 503A bulks list.
Read More
HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?
Published: April 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers rolls out Benefits and taps Novo Nordisk for GLP therapies in weight-loss care as revenue grows, but margins and cash flow tighten.
Read More
Hims & Hers surges 4% as peptide policy shift unlocks growth
Published: April 16, 2026 by: Invezz
Sentiment: Positive
Shares of Hims & Hers Health moved sharply higher on Thursday, extending gains from the previous session after a significant regulatory shift signaled new opportunities in the peptide market. The stock rose about 4% to $25.28 on Thursday morning after closing up 14% on Wednesday, as investors reacted to comments from Robert F.
Read More
Hims & Hers Powers Patient-Provider Connectivity via Digital Platforms
Published: April 14, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS unites telehealth, records and pharmacy fulfillment on one digital platform, adding AI tools, diagnostics and FDA-approved medicines.
Read More
Hims & Hers price target slashed amid GLP-1 transition
Published: April 08, 2026 by: Proactive Investors
Sentiment: Negative
Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple compression and near-term earnings pressures. Shares of Hims & Hers traded hands at about $20 on Wednesday, down almost 39% so far this year.
Read More
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
Published: April 08, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Hims & Hers Health Is No Longer What The Market Thinks
Published: April 08, 2026 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health is evolving from a telehealth provider into a scalable, global consumer health platform with diversified growth drivers. The Novo Nordisk partnership validates HIMS' platform, but execution and regulatory risks in obesity treatments remain material to the thesis. International expansion, notably the Eucalyptus acquisition, and new service categories support robust revenue growth and platform monetization.
Read More
Hims & Hers Advances a Consumer-Centric Digital Health Platform
Published: April 06, 2026 by: Zacks Investment Research
Sentiment: Neutral
HIMS is broadening its digital-first platform with Labs, hormone therapy and weight-loss programs as it scales personalized care globally.
Read More
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Published: April 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
Published: April 01, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, April 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Hims & Hers Expands Personalized Digital Healthcare Platform
Published: March 31, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS builds a digital-first healthcare platform, integrating telehealth, AI and personalized treatments while expanding globally and into new specialties.
Read More
Hims & Hers: The Reset Before The Next Inflection
Published: March 27, 2026 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health shares rallied to ~$27 after the early-March Novo deal before resetting to ~$20, still leaving the stock ~40% above prior coverage levels. Short interest remains elevated at ~83.3M shares (~40% float), while days-to-cover expanded from ~1.0 to ~3.6. Short volume intensity declined from ~62–64% during the selloff to ~45%, signaling reduced marginal short pressure.
Read More
Hims & Hers: Distressed Valuations Will Not Last For Long
Published: March 25, 2026 by: Seeking Alpha
Sentiment: Negative
Hims resolved its legal dispute with Novo Nordisk, removing a major overhang and enabling it to offer branded drugs. Valuations have not recovered to pre-lawsuit levels as persistent insider selling and changes in disclosure have weighed negatively on sentiment. Consensus underestimates the inherent story in Hims emanating from growth in subscribers, sustainability and penetration in new products & markets.
Read More
HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now?
Published: March 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and Doximity are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.
Read More
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
Published: March 25, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Why Is Hims & Hers Health (HIMS) Up 38% Since Last Earnings Report?
Published: March 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?
Read More
INSP vs. HIMS: Which Stock Should Value Investors Buy Now?
Published: March 24, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical Info Systems stocks are likely familiar with Inspire Medical Systems (INSP) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Hims & Hers Expands Integrated Digital Healthcare Ecosystem
Published: March 23, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS builds a seamless digital healthcare ecosystem, expanding into diagnostics, global markets and specialty care to reshape access and delivery.
Read More
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Published: March 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Hims stock jumps 50% as Novo Nordisk ends lawsuit, strikes deal
Published: March 09, 2026 by: Invezz
Sentiment: Positive
Telehealth platforms are becoming a gateway for access to blockbuster weight loss medicines. That shift became clearer on Monday after Novo Nordisk dropped its patent infringement lawsuit against digital health provider Hims & Hers.
Read More
Hims stock jumps 50% as Novo Nordisk ends lawsuit, strikes deal
Published: March 09, 2026 by: Invezz
Sentiment: Positive
Telehealth platforms are becoming a gateway for access to blockbuster weight loss medicines. That shift became clearer on Monday after Novo Nordisk dropped its patent infringement lawsuit against digital health provider Hims & Hers.
Read More
YieldMax® HIMS Option Income Strategy ETF (HIYY) Trading Halt
Published: March 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
MILWAUKEE, March 05, 2026 (GLOBE NEWSWIRE) -- Tidal Investments LLC (“Tidal”) announces that the YieldMax® HIMS Option Income Strategy ETF (NYSE Arca: HIYY) was halted to allow Tidal to evaluate the accuracy of the HIYY Net Asset Values per share (NAVs) published for March 2, 3, and 4, 2026. Tidal determined the NAV for HIYY was required to be restated on March 2 from $12.38 per share to $12.15 per share, on March 3 from $9.92 per share to $11.81 per share and on March 4 from $10.24 per share to $12.13 per share.
Read More
Hims and Hers Expands Its Technology Driven Consumer Health Platform
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its tech-driven care platform with data-led Labs testing, new menopause and testosterone services and global expansion into Canada.
Read More
Hims & Hers Health: Leaving GLP-1s Behind
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers (HIMS) remains a 'Strong Buy' at $16, with fair value estimated at $22 despite recent headwinds. International expansion via the $1.15B Eucalyptus acquisition and product diversification are key drivers, though margins will remain pressured. GLP-1 regulatory risks have intensified, but HIMS is pivoting to diversified growth pillars beyond weight loss.
Read More
Hims' pharmacy partner will reintroduce GLP-1 pill pulled from market, Endpoints News reports
Published: March 03, 2026 by: Reuters
Sentiment: Neutral
Hims & Hers Health's pharmacy partner, Strive Pharmacy, plans to resume sales of its compounded weight‑loss pill through other healthcare providers after halting distribution following U.S. regulatory pushback, Endpoints News reported on Tuesday.
Read More
Carillon Eagle Small Cap Growth Fund Q4 2025 Portfolio Review
Published: March 02, 2026 by: Seeking Alpha
Sentiment: Positive
Coherent is expected to continue to benefit from a transition to products that enable faster throughput speeds, while prior constraints on manufacturing capacity appear to be alleviating. BrightSpring Health Services reported another strong quarter with both revenues and EBITDA up significantly, far outpacing its historical growth rate prior to going public in 2024. Varonis Systems, which provides data protection security software, delivered disappointing earnings results and an outlook below expectations.
Read More
Glancy Prongay Wolke & Rotter LLP Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
Published: March 02, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. IF YOU ARE A HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER, CLICK HERE TO PARTICIPATE. What Happened? On February 7, 2026, The New York Times re.
Read More
Hims expansion may not come in time for risky GLP-1 business
Published: March 02, 2026 by: Reuters
Sentiment: Negative
Telehealth company Hims & Hers Health , known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded GLP-1 sales in the U.S., but that may not happen soon enough for investors who are growing impatient.
Read More
Hims & Hers Expands Digital Health and Global Platform Strategy
Published: February 27, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS expands into labs, cancer screening, menopause and global markets, advancing its digital, subscription-driven healthcare platform and preventive care.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Medical - Equipment & Services
- CEO Andrew Dudum
- Employees 1637